Posts by camerontucker
Everything CGT Global Offers: Starting Materials, Isolated Cells, and Clinical Grade Supply
1. Leukopaks (RUO, Mobilized, Clinical, and GMP Aligned) Leukopaks remain one of the most common upstream inputs for immune cell workflows. We support formats that match how cell therapy teams actually operate. RUO leukopaks Fresh and cryopreserved options for discovery, preclinical, and process development. Mobilized leukopaks Mobilized options for programs requiring higher progenitor content or…
For More InformationCryopreserved Leukopak Viability and Supplier Selection
What to Expect Post Thaw and How to Choose a GMP Partner Cryopreserved leukopaks are getting adopted fast for one simple reason. Fresh starting material creates supply chain risk. Leukopak deliveries can be late, arrive outside temperature requirements, or miss a critical manufacturing window entirely. When that happens, teams do not just lose a leukopak.…
For More InformationGMP Leukopak Partner Guide for Clinical Development
Plus a Fresh vs Cryopreserved Decision Guide for Allogeneic Programs If you are building a cell therapy program, your starting material is not a minor detail. It is one of the biggest drivers of downstream consistency, cost, and timeline risk. That is why the GMP leukopak has become a cornerstone input for teams moving from…
For More InformationAdvancing CAR NK Therapy: Why Leukopak Quality and Donor Characterization Matter
CAR NK therapy is gaining traction as a next wave cell therapy platform. Compared to CAR T, CAR NK programs offer the potential for allogeneic manufacturing, improved safety profiles, and scalable off the shelf products. But CAR NK workflows are less forgiving when it comes to starting material. NK cells are more sensitive to collection…
For More InformationFresh vs Cryopreserved Leukopaks for T Cell Expansion and CAR T Manufacturing
Why the fresh vs cryo decision matters Most CAR T processes are built around predictable inputs. When those inputs shift, it becomes harder to hit target yields, expansion timing, and manufacturing release criteria. Fresh and cryopreserved leukopaks differ in: logistics and scheduling flexibility post processing recovery and expansion behavior sensitivity to handling variables lot to…
For More InformationArmored CAR T
Strengthening T Cells for the Toughest Tumors CAR T therapy changed what is possible in blood cancers. But solid tumors remain one of the toughest frontiers in oncology. Not because we do not know what to target.Because the tumor environment fights back. Solid tumors suppress immune activity, block infiltration, and exhaust T cells before they…
For More InformationBest CD34+ Cell Suppliers for 2026: Comparing Bone Marrow, Cord Blood, and Mobilized Sources
Introduction CD34+ hematopoietic stem and progenitor cells are critical to cell therapy development, gene editing workflows, and translational immunology research. Whether sourced from bone marrow, mobilized peripheral blood, or cord blood, CD34 cell quality and documentation directly influence downstream expansion, differentiation, and functional outcomes. In 2026, research teams are evaluating suppliers based not only on…
For More InformationBest Mobilized Leukopak Suppliers for 2026: G-CSF vs. Plerixafor Compared
Introduction Mobilized leukopaks are essential starting material for advanced cell therapies, immune research, and manufacturing optimization. By mobilizing hematopoietic stem and progenitor cells (HSPCs) from the bone marrow into the bloodstream using agents like G-CSF or plerixafor, researchers can isolate higher yields of CD34+ and target immune cells for CAR T, NK, and other immunotherapy…
For More InformationOptimizing PBMC Viability and Recovery: Updated Best Practices for 2026
In biomedical research, the viability and recovery of peripheral blood mononuclear cells (PBMCs) determine the reliability of downstream results. Over the past few years, advances in donor screening, cryopreservation, and logistics have dramatically improved the consistency of primary immune cell performance. Yet, small variables—temperature shifts, prolonged DMSO exposure, or donor differences—still account for major discrepancies…
For More InformationMeet CGT Global’s Scientific Team: Sophia Johnson Associate Director of Logistic Operations
For cell procurement and delivery operations to run smoothly, countless moving parts must align. From understanding the needs of a research project to scheduling donors, fulfilling orders, and ensuring precise delivery, every step must fit together seamlessly. So, who keeps everything ticking like a perfectly timed clock? Meet Sophia Johnson, Associate Director of Logistic Operations at CGT Global. Sophia has been with…
For More Information